DENISE JOHNSON: Open Payments
NPI 1124226147 · WALDORF, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,723 in 67 payments from 15 companies in 2025. Trend: 2023 $1,800 · 2024 $1,952 · 2025 $1,723
Food & beverage: $1,723
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 13 | $355 |
| AstraZeneca Pharmaceuticals LP | 16 | $349 |
| PFIZER INC. | 8 | $198 |
| Genentech USA, Inc. | 4 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $113 |
| Novartis Pharmaceuticals Corporation | 5 | $107 |
| Boston Scientific Corporation | 1 | $104 |
| Regeneron Healthcare Solutions, Inc. | 4 | $95 |
| GlaxoSmithKline, LLC. | 4 | $92 |
| Amgen Inc. | 3 | $71 |
Products named: DUPIXENT, TEZSPIRE, Xolair, FASENRA, CIBINQO, ENROUTE Transcarotid Neuroprotection System, CUVITRU, TRELEGY ELLIPTA.
Industry payments across MD — which companies pay providers there.
